Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial.

The short version

This 12-month randomized, double-blind, placebo-controlled trial with 272 adults with type 2 diabetes (T2DM) and obesity explored whether curcumin, the active compound in turmeric (Curcuma longa), could protect the pancreatic beta cells that produce insulin. In T2DM, obesity drives insulin resistance (cells responding poorly to insulin), which forces beta cells to work harder until their function starts to decline. Researchers tracked beta-cell function using HOMA-beta, an index calculated from fasting insulin and glucose, alongside HOMA-IR (a related index for insulin resistance) and two hormones made by fat tissue: adiponectin, which improves insulin sensitivity, and leptin, which signals fullness but runs high with excess body fat. Participants, all 35 or older and already taking metformin, were randomly assigned to six capsules a day (1,500 mg total) of standardized curcumin extract or an identical-looking placebo for 12 months, with 115 people in the placebo group and 114 in the curcumin group at randomization. Neither participants nor staff knew who received which capsule. Blood was drawn at baseline and every three months to measure fasting glucose, HbA1c (average blood sugar over about three months), body weight, BMI, insulin, HOMA-beta, HOMA-IR, adiponectin, and leptin. By 12 months, curcumin-treated participants had notably better beta-cell function than the placebo group (HOMA-beta 136.2 vs. 105.2; P<0.01, meaning their beta cells were working more efficiently), a difference that only became significant at 9 and 12 months, suggesting the benefit builds gradually rather than appearing right away. Insulin resistance dropped further with curcumin (HOMA-IR 4.86 vs. 6.04; P<0.001, lower is better), and blood sugar control improved (fasting glucose 115 vs. 131 mg/dL, P<0.05; HbA1c 6.12% vs. 6.47%, P<0.05). The curcumin group also lost more weight (66.1 vs. 69.3 kg, P<0.001) and lowered BMI (25.98 vs. 27.34, P<0.001), while adiponectin rose (14.5 vs. 10.4 ug/mL, P<0.001, more of the "good" fat hormone) and leptin fell (9.4 vs. 20.7 ug/mL, P<0.001, less of the fullness hormone that runs high in obesity). The authors connect these changes to curcumin's anti-inflammatory activity, since inflammation is a known driver of beta-cell decline. Mild side effects, abdominal pain, diarrhea, and headache, occurred in both groups with no one dropping out because of them, and liver and kidney markers stayed normal, suggesting curcumin extract is reasonably safe as a year-long add-on for people already managing T2DM with metformin. Because the trial tested only one dose at a single Thai hospital, it cannot show whether a different dose would work better or whether these results generalize elsewhere. Larger, multi-center trials testing a range of doses would help confirm curcumin's place alongside standard diabetes care.

Key findings

• A 12-month clinical trial found that adults with type 2 diabetes who took 1,500 mg per day of curcumin extract (the active compound in turmeric) had better beta-cell function than those who took a placebo, meaning the insulin-producing cells in their pancreas worked more efficiently by the end of the study.
• Blood sugar control improved measurably: fasting glucose and HbA1c (a measure of average blood sugar over about three months) were both significantly lower in the curcumin group after 12 months.
• Curcumin also reduced insulin resistance (HOMA-IR, a lab measure of how well the body responds to insulin) and led to greater weight loss compared with placebo.
• Two hormones made by fat tissue shifted favorably with curcumin: adiponectin (linked to better insulin sensitivity) rose, while leptin (linked to obesity and inflammation) fell.
• The supplement was well tolerated over the full year, with only mild side effects like stomach upset, and no differences in liver or kidney safety markers compared with placebo.

Common questions